Vision Solutions Introduces Double-Take(R) 7.0 IRVINE,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vision Solutions Introduces Double-Take(R) 7.0

IRVINE, CA--(Marketwired - May 28, 2013) -   Vision Solutions, Inc. , a leading provider of information availability software and services, today announced the release of Double-Take® 7.0, its flagship, affordable solution for SMB, mid-tier and enterprise-level high availability (HA), disaster recovery (DR) and migration for Windows, Linux and cloud computing environments.

Responding to customer feedback, Double-Take 7.0 provides both agentless and agent-based virtual server protection, allowing organizations to protect data, applications and servers in order to maintain business continuity in the manner that best meets the needs of their IT environment. Double-Take 7.0 also provides anything-to-anything migration with near-zero downtime, which makes it easy for IT organizations with heterogeneous environments to move data, applications and workloads between physical, virtual and public or private cloud data centers without affecting users.

"More than half of data center workloads today are virtualized according to IDC's Worldwide Storage Software 2012-2016 Forecast," said Ashish Nadkarni, Research Director for Storage Systems at IDC. "Many enterprises are looking more seriously at the Cloud as well. They need a way to migrate data, applications, even entire environments seamlessly between all three as their needs change. Double-Take 7.0 is the first HA/ DR product to enable this level of anything-to-anything migration, which allows enterprises to place workloads where they make the most sense while protecting them against the types of business interruptions and data loss that can be catastrophic in our always-on, 24x7 world. It solves a growing challenge in businesses of all sizes. "

Eliminating agents removes the need to manage and upgrade each individual agent, reducing labor while ensuring the overall HA/DR technology is always up-to-date. As a result, Double-Take 7.0 easily scales to protect hundreds of physical servers or virtual machines.

Other key features include:

  • Customizable unified status reporting for all assets protected by Double-Take 7.0
  • Near-zero downtime migrations
  • Simple, intuitive graphic user interface (GUI)
  • World-class customer service

"Great care has been taken with this release to deliver a more powerful level of HA, DR and migration than has previously been available from anyone," Alan Arnold, Chief Technology Officer for Vision Solutions, said. "Yet it has also been priced competitively. Double-Take 7.0 provides great short- and long-term value within the ever-changing IT landscape. We believe it will set a new expectation for performance."

Double-Take 7.0 provides HA, DR and migration capabilities for VMware®, Microsoft® Windows® Server and Linux as well as the KVM, Microsoft Hyper-V and Xen hypervisor technologies. More information can be found at visionsolutions.com/DT7 .

About Vision Solutions ( visionsolutions.com )

Vision Solutions® is the premier provider of cloud protection and recovery, high availability, disaster recovery, migration and cross-platform data sharing solutions for IBM Power Systems, Windows, Linux, AIX and cloud computing. Vision Solutions' Double-Take® , iTERA ™ and MIMIX® solutions make it easy for organizations to adopt cloud-based disaster recovery strategies, perform near-zero downtime migrations without risk, share data in real-time across platforms and move, protect and restore data, applications and operating systems of any kind on any combination of physical, virtual or cloud servers. And, not only do our products eliminate downtime, they continue to evolve alongside the most cutting-edge technology on the market.

Contact: Vision Solutions 312-673-6053 Joy.DiNaro@TechImage.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 79

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 72

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 93

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 312

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 87

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohl's Stock Plummets Amid Retail Challenges and Restructuring

Updated Category News Views 589

Kohl's Corporation Faces Significant Challenges Kohl's Corporation (NYSE: KSS) has recently seen its stock plummet to a concerning 52-week low of $13.61. This decline paints a grim picture of the current retail environment, where shifting consumer habits and fierce competition play a pivotal role. Priced at just 0.4 times book value and boasting a generous 14.5% dividend...

Continue Reading
Rapid Micro Biosystems Achieves Record Growth and Future Outlook

Updated Category News Views 136

Financial Performance Highlights for Rapid Micro Biosystems Rapid Micro Biosystems, Inc. (NASDAQ: RPID) has announced impressive results for the fourth quarter and the entire fiscal year of 2024. The company recorded a total revenue of $8.2 million in the fourth quarter, marking a 30% increase compared to the same period in 2023. Likewise, the full year revenue reached...

Continue Reading
ALZpath and Siemens Team Up for Advanced Alzheimer's Testing

Updated Category News Views 265

ALZpath and Siemens Healthineers Form Strategic Partnership ALZpath is thrilled to announce a significant licensing agreement with Siemens Healthineers. This collaboration marks a pivotal enhancement in the accessibility of diagnostic testing for Alzheimer's disease. The agreement involves the use of ALZpath's proprietary pTau217 antibody, a remarkable tool for...

Continue Reading
Generate:Biomedicines Showcases Promising Results for GB-0895

Updated Category News Views 495

Results from Phase 1 Trials of GB-0895 Unveiled Generate:Biomedicines is making notable headlines with its innovative drug GB-0895. This cutting-edge treatment is an ultra-high affinity anti-TSLP monoclonal antibody, specifically designed for individuals grappling with asthma. With a unique formulation, GB-0895 offers a prolonged half-life and sustained pharmacological...

Continue Reading
Driving Growth in Natural Stone Market and Its Future

Updated Category News Views 226

Steady Growth in the Natural Stone Market The natural stone market is on a promising upward trajectory, predicted to rise from USD 37.89 billion to USD 47.63 billion by a future date, indicating a compound annual growth rate (CAGR) of 4.68%. Various factors are driving this growth, most notably the intense infrastructure investment blooming worldwide. The construction...

Continue Reading